Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Items 801–892 of 892
Jiménez, V., & Bosch, F. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch78 · Cited by 1
Subcutaneous administration of adipose-tropic gene therapy for congenital leptin deficiencyPreprint
Cao, L., Huang, W., Xiao, M., & Zou, X. (2025) · Research Square · doi:10.21203/rs.3.rs-7030870/v1 · Cited by 3
“Although AAV vectors are e�cient in delivering transgenes to liver, muscle, brain, and eye (5), its use in gene transfer to adipose tissue—one of largest organs in the body, remains limited largely due to low transduction e�ciency and lack of adipose-tropism of natural AAV serotypes (6).”
The State of the Art and Future of Gene Medicines
Jacobs, F., Gordts, S. C., & Geest, B. D. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse515 · Cited by 1
Strategies for improving adeno-associated viral infection of airway epithelial cells
Dickey, D. D. (2012) · doi:10.17077/etd.m1aiqczb
“diseases, including CF (46-50), α1 antitrypsin deficiency (51, 52), Batten’s disease (53), Canavan’s disease (54), Leber’s congenital amaurosis (55-58), hemophilia B (59, 60), lipoprotein lipase deficiency (61-63), Pompe’s disease (64), Parkinson’s disease (65-70),”
BackgroundGene Therapy Trials in Hemophilia A and B
High, K. A. (2014) · Wiley eBooks · doi:10.1002/9781118398258.ch41
Self-citationSteines, B. R., Zabner, J., Meier, J. L., Adams, C. M., McCray, P. B., & Yeaman, C. A. (2015) · doi:10.17077/etd.tdj11wfe
Design and recombinant production of combinatorial peptide libraries for gene delivery
de Raad, M. (2013) · Utrecht University Repository (Utrecht University)
Fernandez-Moure, J. S., Eps, J. L. V., Weiner, B. K., Ferrari, M., & Tasciotti, E. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8065-6_19
Gene Therapy for Hereditary Hearing Loss
McDougald, D. S., Cunningham, L. L., & Chien, W. W. (2013) · Perspectives on Hearing and Hearing Disorders Research and Diagnostics · doi:10.1044/hhd17.1.5
UNDERSTANDING THE SOLUTION-PHASE BIOPHYSICS AND CONFORMATIONAL DYNAMICS OF VIRUS CAPSIDS
Rayaprolu, V. (2013) · Montana State University ScholarWorks (Montana State University)
Progress and challenges in gene therapy for Crigler–Najjar syndrome
Aronson, S. J., Beuers, U. H., & Bosma, P. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1100991 · Cited by 1
Yu, D. L. (2015) · The Atrium (University of Guelph)
Treating Hemophilia by Gene Therapy
Porada, C. D., Ignacio, G., Atala, A., & Almeida-Porada, G. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800548-4.00012-7
Serotype 8 Capsid of Adeno-Associated Virus Mapping a Neutralizing Epitope onto the
Agbandje‐McKenna, M., Baker, T. S., Kleinschmidt, J. A., Naumer, M., Olson, N. H., Ng, R., Gurda, L., Raupp, C., & Popa-Wagner, R. (2012)
Gene Transfer in Spinal Muscular Atrophy
Foust, K. D., & Kaspar, B. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00019-7
Martin, C., Mayer, C., Qiao, C., Yuan, Z., Yang, L., Li, J., Li, J., & Xiao, X. (2015) · Molecular Therapy · doi:10.1016/s1525-0016(16)33926-0
Biology of AAV Vectors in the Central Nervous System
Murlidharan, G. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/cr64-be62
Warischalk, J. K. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dqdt-1s58 · Cited by 1
Foamy virus vector integration and application in gene therapy
Sweeney, N. P. (2015) · Spiral (Imperial College London) · doi:10.25560/50704
Interactions of Cells with Magnetic Nanowires and Micro Needles
Perez, J. E. (2017) · King Abdullah University of Science and Technology Repository (King Abdullah University of Science and Technology) · doi:10.25781/kaust-y87mb
基于CRISPR/Cas9基因编辑技术的人类遗传疾病基因治疗相关研究进展
门, 可., 段, 醒., 杨, 阳., & 魏, 于. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00169 · Cited by 1
Chand, A. (2012) · Mspace (University of Manitoba)
Arvanian, V. L., & Petrosyan, H. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00015-6
Targeting Astrocytes With Viral Gene Therapy for Alzheimer’s Disease
Rosenthal, Z. P., Kraft, A. W., Czerniewski, L. R., & Lee, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00005-3 · Cited by 1
Thérapie génique du diabète de type 1 : quelles avancées ?
Dubois‐Laforgue, D. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70785-0
The Role of Synaptic Inhibition in the Primary Motor Cortex of an ALS Mouse Model
Place, K. M. (2018) · TSpace (University of Toronto)
Rajendran, J. (2019) · Helda - University of Helsinki Institutional Repository
Systemic Delivery in Anti-aging Medicine: An Overview
Wang, Y., & Lai, W. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-54490-4_1 · Cited by 1
結核菌の縦列反復配列多型(VNTR)解析に基づく分子疫学とその展望 : 大阪市の例
和田, 崇., & 長谷, 篤. (2010) · 結核
Viscomi, C. F., & Zeviani, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-05517-2_22
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Self-citationGene Therapy: Vector Technology and Clinical Applications
Sunyong, T., & Cornetta, K. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4800-6_13
(2011) · Elsevier eBooks · doi:10.1016/b978-0-12-385212-0.16001-9
Conboy, I. M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733450908.793553930
(2019) · Elsevier eBooks · doi:10.1016/b978-3-437-21882-8.00026-8
Strecker, M. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68021
The DARPin Encyclopedia: from Basic Research Towards TherapeuticsPreprint
Wild, P. S., Eapen, R., Forrer, P., & Jost, C. (2022) · Preprints.org · doi:10.20944/preprints202206.0147.v1 · Cited by 1
The DARPin Encyclopedia: from Basic Research Towards TherapeuticsPreprint
Wild, P. S., Eapen, R., Forrer, P., & Jost, C. (2022) · Preprints.org · doi:10.20944/preprints202206.0147.v2
Genome Editing with CRISPR‐Cas Systems
Lotfy, P., & Hsu, P. D. (2022) · Wiley eBooks · doi:10.1002/9781683673798.ch11 · Cited by 1
Lopes, L. D. S. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2022.tde-08112022-173318
Gene Editing and Gene Therapies in Cancer Treatment
Tripathi, G., Faiyaz, M., Hasan, Z., Khanam, A., & Husain, A. (2023) · IGI Global eBooks · doi:10.4018/979-8-3693-3026-5.ch032
Electric pulse exposure reduces AAV8 dosage required to transduce HepG2 cells
Yao, Y., Holdcraft, R. W., Hagness, S. C., & Booske, J. H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298866
Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Tran, N. M., Xu, X., Qi, L. S., & Hu, Y. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_19 · Cited by 1
Publication trends of Leber congenital amaurosis researches: a bibliometric study during 2002-2022
Huang, X.-X., Xie, M., Sun, Y.-Q., Zhao, X., Chen, Y., Chen, J., Han, S.-Y., Zhou, M., & Sun, X. (2024) · International Journal of Ophthalmology · doi:10.18240/ijo.2024.08.17 · Cited by 2
“Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges [21] High, Katherine A.”
BackgroundHarnessing natural killer cells engineering for cancer immunotherapy
Hao, Y., & Andersson, T. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i2.6431
USE OF GENE THERAPY IN THE TREATMENT OF ALZHEIMER’S DISEASE – LITERATURE REVIEW
Sanches, J. C., Novais, P. C., Martins, M. C., Neto, J. A. P., Domingues, P. H. L., Lopes, E. R., Marques, E. B., Nascimento, I. A., Vitoreli, R. B., & da Costa, I. B. (2024) · Aracê. · doi:10.56238/arev6n4-304
AAV2 serotype demonstrates the highest transduction efficiency in porcine lung-derived cells
Ju, W. S., Kim, S., Choi, A., Lee, J.-Y., Lee, H., No, J.-G., Lee, S., Oh, K. B., & Yoo, J. G. (2015) · Journal of Animal Reproduciton and Biotechnology · doi:10.12750/jarb.39.4.254 · Cited by 1
González, S. T., & Oppenheimer, C. W. (2025) · Anales de la Real Academia Nacional de Farmacia · doi:10.53519/analesranf.2025.91.01.03
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00033-7
Neuhofer, C. M., Gasser, T., & Klopstock, T. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00027-1
Retinal Epithelial Neutralization Assay Optimizes AAV Serotype Selection for Ocular Gene Therapy
Li, Y., Chen, Y., Huo, N., Jia, Z., Huang, H., Zhao, Z., Wu, S., & Hou, L. (2025) · Viruses · doi:10.3390/v17070988
Editorial: Molecular mechanisms and treatment of monogenic skeletal disorders
Xu, C., Xia, W., Ebeling, P. R., & Wang, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1666528
“Furthermore, gene therapy has emerged as a promising approach for treating genetic disorders by directly correcting the underlying genetic defects (8, 9).”
Integrative Approach Towards Treatment of Alzheimer's and Other Dementias
Khan, N. A., Sambyal, N., Tanzeelah, Sachdeva, P., Siwan, D., Rehman, A., Dey, A., Ghosh, S., Mahajan, A. A., Rizvi, S., et al. (2025) · Wiley eBooks · doi:10.1002/9781394336807.ch8
Yıldız, U., ALTINOK, İ., Arslan, H., & Çoban, B. (2025) · Journal of Chemical Sciences · doi:10.1007/s12039-025-02436-0
“1,2 For these reasons, non-viral deliveries are attractive alternatives to viral systems for DNA delivery.”
Cui, J., Wang, W., Liu, D., Han, D., Jin, X., & Wei, W. (2025) · Human Gene Therapy · doi:10.1177/10430342251393707
Omeje, E. I., Ugwuanyi, D. C., Nnabuchi, M. A., Nweze, O. C., Nzotta, N. R., Ugwu, S. M., & Omojola, A. D. (2025) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2025.17.3.3352
Breton, C. A., Clark, P., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.11999370
Additional file 1 of Liposome-lentivirus for miRNA therapy with molecular mechanism study
Fen, S., Chen, H., Dai, X., Hou, Y., Li, J., Zhang, Y., 黄来强, Guo, B., & Yang, D. (2024) · Figshare · doi:10.6084/m9.figshare.26011767
Chauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2024) · Figshare · doi:10.6084/m9.figshare.26952309
Kim, M., Oh, S., Kim, S., Kim, I.-S., Kim, J., Han, J., Ahn, J. W., Chung, S., Jang, J.-H., Shin, J. E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26749988
Kim, M., Oh, S., Kim, S., Kim, I.-S., Kim, J., Han, J., Ahn, J. W., Chung, S., Jang, J.-H., Shin, J. E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26749997
Breton, C. A., Clark, P. M., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.11999367
Breton, C. A., Clark, P., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.11999373
Kim, M., Oh, S., Kim, S., Kim, I.-S., Kim, J., Han, J., Ahn, J. W., Chung, S., Jang, J.-H., Shin, J. E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750000
Kim, M., Oh, S., Kim, S., Kim, I.-S., Kim, J., Han, J., Ahn, J. W., Chung, S., Jang, J.-H., Shin, J. E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26749991
Kim, M., Oh, S., Kim, S., Kim, I.-S., Kim, J., Han, J., Ahn, J. W., Chung, S., Jang, J.-H., Shin, J. E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26749994
Lee, M. H., Kang, S., Um, K.-H., Lee, S. W., Hwang, H., Baek, K., & Choi, J. W. (2024) · Figshare · doi:10.6084/m9.figshare.24995558
Kim, M., Oh, S., Kim, S., Kim, I.-S., Kim, J., Han, J., Ahn, J. W., Chung, S., Jang, J.-H., Shin, J. E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26749985
AAV vectors for cancer gene therapy
Lee, M., Park, J., Park, J. H., & Curiel, D. T. (2026) · Advances in cancer research · doi:10.1016/bs.acr.2026.02.005
The Deubiquitinating Enzyme Otub2 Modulates Pancreatic Beta-Cells Function and Survival
Oshry, M., Isaac, R., Boura‐Halfon, S., Casana, E., Sampson, S. R., Lev, S., Bosch, F., Zick, Y., & Vinik, Y. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl44406
Characterization of rAAV vectors packaging in baculovirusinfected insect cells
Penaud‐Budloo, M. (2018) · theses.fr (ABES) · doi:10.70675/c5cff6daz8fe4z430cz80e6z97a11cc59c8e
Bella, T. L. (2018) · theses.fr (ABES) · doi:10.70675/e88d9a08za929z4c0fzb8d9z9f01cd69ca39
Garcia, R. A. G. (2020) · theses.fr (ABES) · doi:10.70675/3efaf973z49ccz4fa2zaa8ezaf9a0060ddd9
Nouvelle génération d’AAV : un mélange de chimie organique et de vectorologie
Lalys, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/b6df86c2z6520z473ez9e10ze1740b9bc3ae
The future of hematopoietic stem cell and stem cell gene therapy for metabolic diseases
Vijayasekharan, K., Donald, A., Ghosh, A., & Wynn, R. F. (2026) · Regenerative Medicine · doi:10.1080/17460751.2026.2681399
Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience
Саматошенков, И. В., Zakirova, E. Y., Samatoshenkova, J. M., Rizvanov, A. A., & Mukhamedshina, Y. O. (2026) · Cells · doi:10.3390/cells15121104 · Cited by 1
“Ad vectors may induce significant innate immune activation and transient systemic inflammatory reactions, while pre-existing neutralizing antibodies against AAV vectors may limit transduction efficiency in humans [156].”
Yan, C., & Li, J. (2026) · Research Square · doi:10.21203/rs.3.rs-9670512/v1
Hepatocyte OTUD1 deubiquitinates and activates ERK1/2 to promote acetaminophen-induced liver injury
Wang, M., Zhao, Y., Zhang, Q., Chen, K., Wang, M., Zhang, Y., Zhu, W., Lou, S., Jin, L., Zuo, W., et al. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168383
Zemmouchi, M., Fermawi, A. E., Benagdi, A., Baaziz, S., & Hiram, R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119824
Critical evaluation of the impact of ssDNA cargo length on AAV stability – a case study
He, J., Azami, M., Vangjeli, K., Afroz, S., Galibert, L., Banazadeh, A., Ali, A., Nguyen, T.-A., Deng, K., Singh, R., et al. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04176-3
“AAVs are composed of a capsid protein encapsulating a single-stranded DNA (ssDNA) genome of approximately 4.7 kb in length [1, 2, 7, 8].”
InfluentialMyogenic Fusogen‐Engineered Lipid Nanoparticles Enhance mRNA Delivery in Skeletal Muscle
Zhang, F., Xu, Z., Duan, Y., Sun, Y., Wu, S., Long, T., Durbacz, M. Z., Zhang, L., Xiao, Y., Pien, Y.-C., et al. (2026) · Advanced Functional Materials · doi:10.1002/adfm.78165
Sánchez-Gutierrez, C., Bohorquez-Zambrano, L. F., Garnica-Álvarez, C., Rincón, M. Y., & Valderrama‐Aguirre, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1925844 · Cited by 1
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.